Literature DB >> 27809664

Liver Surface Nodularity Score Allows Prediction of Cirrhosis Decompensation and Death.

Andrew D Smith1, Kevin A Zand1, Edward Florez1, Reza Sirous1, Darya Shlapak1, Frederico Souza1, Manohar Roda1, Jason Bryan1, Amit Vasanji1, Michael Griswold1, Seth T Lirette1.   

Abstract

Purpose To determine whether use of the liver surface nodularity (LSN) score, a quantitative biomarker derived from routine computed tomographic (CT) images, allows prediction of cirrhosis decompensation and death. Materials and Methods For this institutional review board-approved HIPAA-compliant retrospective study, adult patients with cirrhosis and Model for End-Stage Liver Disease (MELD) score within 3 months of initial liver CT imaging between January 3, 2006, and May 30, 2012, were identified from electronic medical records (n = 830). The LSN score was measured by using CT images and quantitative software. Competing risk regression was used to determine the association of the LSN score with hepatic decompensation and overall survival. A risk model combining LSN scores (<3 or ≥3) and MELD scores (<10 or ≥10) was created for predicting liver-related events. Results In patients with compensated cirrhosis, 40% (129 of 326) experienced decompensation during a median follow-up period of 4.22 years. After adjustment for competing risks including MELD score, LSN score (hazard ratio, 1.38; 95% confidence interval: 1.06, 1.79) was found to be independently predictive of hepatic decompensation. Median times to decompensation of patients at high (1.76 years, n = 48), intermediate (3.79 years, n = 126), and low (6.14 years, n = 152) risk of hepatic decompensation were significantly different (P < .001). Among the full cohort with compensated or decompensated cirrhosis, 61% (504 of 830) died during the median follow-up period of 2.26 years. After adjustment for competing risks, LSN score (hazard ratio, 1.22; 95% confidence interval: 1.11, 1.33) and MELD score (hazard ratio, 1.08; 95% confidence interval: 1.06, 1.11) were found to be independent predictors of death. Median times to death of patients at high (0.94 years, n = 315), intermediate (2.79 years, n = 312), and low (4.69 years, n = 203) risk were significantly different (P < .001). Conclusion The LSN score derived from routine CT images allows prediction of cirrhosis decompensation and death. ©RSNA, 2016 Online supplemental material is available for this article.

Entities:  

Mesh:

Year:  2016        PMID: 27809664     DOI: 10.1148/radiol.2016160799

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  17 in total

1.  Prediction of post TIPS hepatic encephalopathy: are we there yet?

Authors:  Sanchit Sharma; Ashish Chauhan; Anoop Saraya
Journal:  Hepatol Int       Date:  2021-06-11       Impact factor: 6.047

2.  CT-based liver surface nodularity for the detection of clinically significant portal hypertension: defining measurement quality criteria.

Authors:  Riccardo Sartoris; Marie Lazareth; Arianna Nivolli; Marco Dioguardi Burgio; Valérie Vilgrain; Maxime Ronot
Journal:  Abdom Radiol (NY)       Date:  2020-09

Review 3.  Imaging of Hepatic Fibrosis.

Authors:  Rishi Philip Mathew; Sudhakar Kundapur Venkatesh
Journal:  Curr Gastroenterol Rep       Date:  2018-08-29

4.  Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD.

Authors:  Marco Dioguardi Burgio; Riccardo Sartoris; Aurélie Beaufrere; Jules Grégory; Boris Guiu; Chloé Guillot; Pierre-Emmanuel Rautou; Laurent Castera; Mohamed Bouattour; Valérie Paradis; Valérie Vilgrain; Maxime Ronot
Journal:  Eur Radiol       Date:  2021-09-17       Impact factor: 7.034

5.  Multiparametric CT for Noninvasive Staging of Hepatitis C Virus-Related Liver Fibrosis: Correlation With the Histopathologic Fibrosis Score.

Authors:  Perry J Pickhardt; Peter M Graffy; Adnan Said; Daniel Jones; Brandon Welsh; Ryan Zea; Meghan G Lubner
Journal:  AJR Am J Roentgenol       Date:  2019-01-15       Impact factor: 3.959

6.  Computed Tomography-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related Hepatocellular Carcinoma.

Authors:  Martin Seror; Riccardo Sartoris; Christian Hobeika; Mohamed Bouattour; Valérie Paradis; Pierre-Emmanuel Rautou; Olivier Soubrane; Valérie Vilgrain; François Cauchy; Maxime Ronot
Journal:  Ann Surg Oncol       Date:  2020-09-23       Impact factor: 5.344

7.  Automated CT and MRI Liver Segmentation and Biometry Using a Generalized Convolutional Neural Network.

Authors:  Kang Wang; Adrija Mamidipalli; Tara Retson; Naeim Bahrami; Kyle Hasenstab; Kevin Blansit; Emily Bass; Timoteo Delgado; Guilherme Cunha; Michael S Middleton; Rohit Loomba; Brent A Neuschwander-Tetri; Claude B Sirlin; Albert Hsiao
Journal:  Radiol Artif Intell       Date:  2019-03-27

8.  Intraindividual comparison of MRI-derived liver surface nodularity score at 1.5 T and 3 T.

Authors:  Weon Jang; Ji Soo Song; Tae-Hoon Kim; Kwon-Ha Yoon
Journal:  Abdom Radiol (NY)       Date:  2022-01-21

9.  CT texture analysis of the liver for assessing hepatic fibrosis in patients with hepatitis C virus.

Authors:  Meghan G Lubner; Daniel Jones; John Kloke; Adnan Said; Perry J Pickhardt
Journal:  Br J Radiol       Date:  2018-10-11       Impact factor: 3.039

Review 10.  Noninvasive staging of liver fibrosis: review of current quantitative CT and MRI-based techniques.

Authors:  Won Hyeong Im; Ji Soo Song; Weon Jang
Journal:  Abdom Radiol (NY)       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.